ESR1 and breast carcinoma: ADELA (NCT06382948) is a phase III trial, where elacestrant combined with everolimus is compared to elacestrant alone in the ER+/HER2− advanced breast cancer population with ESR1-mutated tumors that have progressed on ET and CDK4/6i.